Search

Your search keyword '"Kaidashev I"' showing total 300 results

Search Constraints

Start Over You searched for: Author "Kaidashev I" Remove constraint Author: "Kaidashev I"
300 results on '"Kaidashev I"'

Search Results

1. MMUNOLOGICAL FEATURES OF MACROPHAGES ASSOCIATED WITH METASTASIS OF PRIMARY BREAST CARCINOMA INTO REGIONAL LYMPH NODES

2. THE ROLE OF POLYMORPHISM OF THE COLLAGEN GENE 1 TYPE OF ALPHA-2 (COL1A2) (RS42524) IN THE DIAGNOSTIC METHODS OF THE EVALUATION OF POST-OPERATIVE SKIN SCARS LOCALIZED IN DIFFERENT AREAS OF THE HEAD AND NECK

3. QUANTITATIVE CHARACTERISTICS OF CD68+ AND CD163+ MACROPHAGES IN THE PRIMARY FOCUS AND IN METASTATIC LESIONS OF REGIONAL LYMPH NODES IN TRIPLE-NEGATIVE INVASIVE BREAST CARCINOMA

4. IL-26 in the induced sputum is associated with the level of systemic inflammation, lung functions and body weight in COPD patients

5. Erratum to: Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

9. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

12. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis

13. Rhinitis associated with asthma is distinct from rhinitis alone:The ARIA-MeDALL hypothesis

14. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

16. The ARIA-MeDALL hypothesis

17. Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

18. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air ® App

19. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

20. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement

23. Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model

24. The Allergic Rhinitis and its Impact on Asthma (ARIA) Approach of Value-Added Medicines: As-Needed Treatment in Allergic Rhinitis

25. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air® real-world data

26. Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air

27. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

28. Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air

29. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

30. Aligning the good practice mask with the objectives of the European innovation partnership on active and healthy ageing

32. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation

34. Management of anaphylaxis due to COVID-19 vaccines in the elderly

37. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy'

38. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

39. Aligning the good practice mask with the objectives of the European innovation partnership on active and healthy ageing

40. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

46. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement

50. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

Catalog

Books, media, physical & digital resources